Development of polydopamine based theranostic carriers

In this study, polydopamine (PDA) and PDA-Ce6 nanoparticles (NP) were synthesized in varying size ranges. The images of the synthesized nanoparticles were taken by scanning electron microscopy (SEM), and their characterizations were made. It was observed that the addition of 2-propanol (IPA) to the synthesis environment inhibited the reaction and reduced the particle size, while increasing the amount of dopamine hydrochloride increased the particle size. Photothermal therapy (FTT) potentials of PDA NPs and PDA-Ce6 NPs were investigated. The results show that 200 nm PDA, 500 nm PDA and PDA-Ce6 NPs are usable agents in FTT. The photodynamic therapy (FDT) potential of PDA-Ce6 NPs was investigated and it was observed that the production of reactive oxygen radicals (ROS) was at a level that could be used in PDT. In-vitro cell experiments were performed with L929 and T98G cell lines. In cytotoxicity experiments, it was clear that both 200 nm PDA NPs and PDA-Ce6 NPs were have low cytotoxicity. FTT experiments of 200 nm PDA NPs and FTT, FDT and combined FTT-FDT experiments of PDA-Ce6 NPs were performed. It was observed that 200 nm PDA NPs killed 45% of the cells in the medium at 100 μg/ml NP concentration as a result of FTT application. It was found that PDA-Ce6 NPs killed 53% of the cells in the medium at 100 μg/ml NP concentration in FTT application, 49% in FDT application and 58% in combined FTT-FDT application.